Pfizer (PF) announced that its oral drug tofacitinib in doses of 5 mg and 10 mg twice daily met Phase 3 endpoints on psoriatic arthritis. The trial was conducted on adult patients with active psoriatic arthritis (PsA). The recruited patients had an inadequate response to at least one conventional anti-rheumatic drug (csDMARD) and were tumor necrosis factor inhibitor (TNFi)-naïve.
Patients enrolled in the study were required to be on one csDMARD as background therapy and continue that dose for the duration of the study. The study included adalimumab 40 mg subcutaneously administered every 2 . . .